Heart Replacement Articles & Analysis
12 news found
A summary of the abstracts are as follows: The REMOVE (“Revealing Mechanisms and Investigating Efficiency Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis“) investigator initiated randomized, controlled trial enrolled 288 patients with documented infective endocarditis with a EuroSCORE II (European System for Cardiac ...
The Carmat artificial heart will be marketed under the Aeson® brand name. In view of the 3 unique features of the product – pulsatility[2], autoregulation2 and hemocompatibility[3] – CARMAT creates a new product category: the Physiologic Heart Replacement Therapy[4] (PHRT). ...
ByCarmat
Neuchâtel, Switzerland, February 22, 2019 – Novostia announces that it raised CHF 6.5 million from private investors to advance its disruptive aortic and mitral heart valve to clinical trials. Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve ...
Colibri’s proprietary TAVI system features a replacement heart valve pre-mounted and pre-crimped on a balloon delivery catheter, pre-loaded into a low-profile access sheath and sterilized, ready-for-use from package to patient. ...
” The ongoing EFS will enroll up to 10 individuals with severe aortic stenosis, who will be implanted with Colibri’s second-generation 24mm or 27mm percutaneous aortic heart valve in a TAVI procedure. This proprietary TAVI system features a replacement heart valve pre-mounted and pre-crimped on a balloon delivery catheter, pre-loaded ...
As with Colibri’s earlier generation system, this TAVI system contains a replacement aortic heart valve that is pre-mounted, and pre-crimped on a balloon delivery catheter, loaded into a low-profile access sheath and sterilized, ready-for-use from package to patient. ...
Colibri Heart Valve, LLC, a privately held medical device company, has been granted yet another patent directed to prosthetic heart valves. More particularly, today the U.S. Patent & Trademark Office granted Colibri U.S. Patent No. 8,361,144 entitled, “Percutaneously Deliverable Heart Valve Device And Methods Associated Therewith.” The patent is directed to a method of making a ...
“The Colibri TAVI System is designed to address the expanding patient populations including those in the emerging markets which the company is preparing to pursue globally through our Chinese joint venture, Venibri Medtech.” A crimped and loaded heart valve on a delivery catheter which is pre-packaged and ready-for-use, provides significant time, cost and safety ...
” A pre-packaged, ready-for-use, THV System provides significant time and cost benefits associated with a transcatheter heart valve replacement procedure and is ideally suited for expanding the use of this treatment modality into emerging world markets. With the strengthened patent portfolio, Colibri is positioned to advance clinical development of both ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Patent No. 9,125,739 (the “’739 Patent”) titled, “Percutaneous Replacement Heart Valve and a Delivery and Implantation System.” This will be Colibri’s 12th allowed/granted patent and will issue on September 8, 2015. ...